GANX GAIN THERAPEUTICS INC Product Launches 8-K Filing 2024 - Preclinical Data Release Gain Therapeutics, Inc. announced promising preclinical data for its product candidate GT-02287, showing significant improvements in motor and cognitive functions in animal models of GBA-1 and Parkinson's disease, with effects lasting over a week after treatment cessation.Get access to all SEC 8-K filings of the GAIN THERAPEUTICS INC